Organon & Co.
XTRA:7XP 株式レポート
Organon マネジメント Organonの CEO はKevin Aliで、 Jun2021年に任命され、 の在任期間は 3.08年です。 の年間総報酬は$ 14.83Mで、 8.4%給与と91.6%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.053%を直接所有しており、その価値は€ 2.57M 。経営陣と取締役会の平均在任期間はそれぞれ3.1年と3.1年です。
主要情報 CEO給与比率 8.4% CEO在任期間 3.1yrs CEOの所有権 0.05% 経営陣の平均在職期間 3.1yrs 取締役会の平均在任期間 3.1yrs
経営陣の近況
Organon & Co., Annual General Meeting, Jun 04, 2024 Apr 28 Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024 Dec 06
すべての更新を表示
Organon & Co. Updates on FDA Review of VTAMA (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older Nov 05 Organon & Co. Revises Earnings Guidance for the Full Year 2024
Organon & Co. (NYSE:OGN) completed the acquisition of Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others. Oct 28
Organon & Co. to Report Q3, 2024 Results on Oct 31, 2024 Oct 09
Shanghai Henlius Biotech, Inc. and Organon Announces Phase 3 Comparative Clinical Study of Perjeta®? (pertuzumab) Biosimilar Candidate HLX11 Oct 01 Organon & Co. (NYSE:OGN) agreed to acquire Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others for approximately $1.2 billion. Sep 18
Organon & Co. Affirms Revenue Guidance for the Full Year 2024
Organon & Co. to Report Q2, 2024 Results on Aug 06, 2024 Jul 10
Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14 May 25 Organon & Co. Provides Earnings Guidance for the Year 2023
Organon & Co., Annual General Meeting, Jun 04, 2024 Apr 28
Organon & Co. to Report Q1, 2024 Results on May 02, 2024 Apr 09 US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary
Fourth quarter dividend of US$0.28 announced Feb 18
Organon & Co. Provides Earnings Guidance for the Year 2024 Feb 16 Organon & Co. Declares Quarterly Dividend, Payable on March 14, 2024
Organon & Co. to Report Q4, 2023 Results on Feb 15, 2024 Feb 02
Investor sentiment improves as stock rises 21% Jan 12
Organon’S Xaciato (Clindamycin Phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older Jan 10 Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024 Dec 06
Investor sentiment deteriorates as stock falls 31% Nov 29
Samsung Bioepis & Organon Announces FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (Adalimumab-bwwd) Nov 09
Samsung Bioepis & Organon Announces FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (Adalimumab-bwwd) Nov 08
Organon & Co. Declares a Quarterly Dividend, Payable on December 14, 2023 Nov 04
Organon & Co. Declares a Quarterly Dividend, Payable on December 14, 2023 Nov 03
Third quarter 2023 earnings released: EPS: US$0.23 (vs US$0.89 in 3Q 2022) Nov 03 Organon & Co. to Report Q3, 2023 Results on Nov 02, 2023 Oct 20
CEO報酬分析 Organon の収益と比較して、Kevin Ali の報酬はどのように変化したか？ 日付 総報酬 給与 会社業績 Mar 31 2024 n/a n/a US$1b
Dec 31 2023 US$15m US$1m US$1b
Sep 30 2023 n/a n/a US$585m
Jun 30 2023 n/a n/a US$754m
Mar 31 2023 n/a n/a US$746m
Dec 31 2022 US$14m US$1m US$917m
Sep 30 2022 n/a n/a US$1b
Jun 30 2022 n/a n/a US$1b
Mar 31 2022 n/a n/a US$1b
Dec 31 2021 US$19m US$1m US$1b
報酬と市場: Kevinの 総報酬 ($USD 14.83M ) は、 German市場 ($USD 3.40M ) の同規模の企業の平均を上回っています。
報酬と収益: Kevinの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者 Mr. Kevin Ali is Chief Executive Officer and Director of Organon & Co. since June 2, 2021. Mr. Ali served as the President of Global Enterprise Portfolio Strategy at Merck & Co., Inc. from 2019 to 2021 and ... Show more
リーダーシップ・チーム 名称 ポジション 在職期間 報酬 所有権 CEO & Director 3.1yrs US$14.83m 0.053% € 2.6m Executive VP & CFO 3.1yrs US$5.21m 0.034% € 1.7m Executive VP 1.5yrs US$3.19m 0.011% € 555.2k Executive VP & Chief Commercial Officer 3.5yrs US$3.84m 0.020% € 964.5k Executive VP and Head of Manufacturing & Supply 3.1yrs US$3.74m 0.016% € 777.4k Executive VP & Chief Information Officer 3.1yrs データなし 0.019% € 918.4k Head of Investor Relations 3.5yrs データなし データなし Chief Ethics & Compliance Officer no data データなし データなし Chief Communications Officer no data データなし データなし Chief Business Development Officer no data データなし データなし Executive VP & Chief Human Resources Officer 3.1yrs データなし 0.012% € 579.2k Executive VP & Head of Global Business Services 3.1yrs データなし 0.0087% € 425.9k
もっと見る
経験豊富な経営陣: 7XPの経営陣は 経験豊富 であると考えられます ( 3.1年の平均在職年数)。
取締役 名称 ポジション 在職期間 報酬 所有権 CEO & Director 3.1yrs US$14.83m 0.053% € 2.6m Independent Chairman of the Board 3.1yrs US$450.00k データなし Independent Director 3.1yrs US$335.00k データなし Independent Director 3.1yrs US$320.00k 0.00025% € 12.2k Independent Director 3.1yrs US$320.00k データなし Independent Director 3.1yrs US$330.00k データなし Independent Director 3.1yrs US$320.00k データなし Independent Director 3.1yrs US$345.00k 0% € 0 Independent Director 3.1yrs US$320.00k データなし Independent Director 3.1yrs US$330.00k データなし Independent Director 3.1yrs US$320.00k 0% € 0 Independent Director 3.1yrs US$330.00k 0% € 0
もっと見る
経験豊富なボード: 7XPの 取締役会 は 経験豊富 であると考えられます ( 3.1年の平均在任期間)。
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}